Learn about the benefits of Spravato for depression, how esketamine works, who may benefit, and what to expect from supervised treatment.
When depression doesn’t improve enough with standard treatment, it can be frustrating to keep searching for an approach that works.
For adults with treatment-resistant depression (TRD), Spravato (esketamine) is one treatment option that may be considered. Unlike traditional antidepressants, Spravato is an esketamine nasal spray administered under direct medical supervision.
The benefits of Spravato for depression can include providing another treatment pathway when previous antidepressant treatments have not provided adequate relief. However, it isn’t appropriate for everyone, and treatment requires careful medical evaluation and monitoring.
So, what makes Spravato different?
Spravato is the brand name for esketamine nasal spray, a prescription medication used in specific adults with depression.
The FDA currently approves Spravato for:
One of the most important benefits of Spravato for depression is that it provides another treatment option for adults whose depression has not improved adequately with previous treatments.
Treatment-resistant depression can be exhausting. Someone may have tried more than one antidepressant and still experience significant symptoms. Spravato offers a different therapeutic approach that a qualified clinician can evaluate as part of an individualized treatment plan.
Many commonly prescribed antidepressants primarily influence neurotransmitter systems such as serotonin or norepinephrine. Esketamine works differently.
It is an NMDA receptor antagonist that acts on the brain’s glutamate system. This distinct mechanism is one reason researchers have investigated esketamine as an option for people whose depression has not responded adequately to conventional antidepressant treatment.
That doesn’t mean it simply “resets” the brain. Depression is much more complicated than that. The important point is that Spravato offers a different pharmacological approach.
An important change reflected in current FDA labeling is that Spravato can be used as monotherapy or in conjunction with an oral antidepressant for treatment-resistant depression in adults.
This gives clinicians more flexibility when developing an individualized treatment plan. Whether Spravato alone or alongside an oral antidepressant is appropriate depends on the patient’s circumstances, medical history, previous treatments, and clinician’s assessment.
Spravato isn’t intended to be used independently at home.
Because esketamine can cause sedation, dissociation, respiratory depression, and increases in blood pressure, treatment is administered in a certified healthcare setting with appropriate monitoring.
The current prescribing information requires monitoring for at least two hours after administration, with assessment before the patient leaves the healthcare setting.
For patients and their families, this supervised approach is an important part of the treatment’s safety requirements.
Depression doesn’t respond identically to every treatment. For some people, conventional antidepressants and psychotherapy provide substantial improvement. For others, symptoms remain despite appropriate treatment.
That’s where alternative or additional treatment approaches may become part of the conversation.
Spravato isn’t necessarily the next step for everyone. Instead, it is one option a qualified mental health professional may consider when evaluating treatment-resistant depression.
Spravato contains esketamine, which is related to ketamine but is a distinct prescription medication and is administered as a nasal spray. Esketamine acts as an NMDA receptor antagonist and influences the glutamate neurotransmitter system.
This differs from many traditional antidepressants and may help explain why it has a place in treatment-resistant depression care.
Still, it’s important not to oversimplify the science. Depression involves multiple biological, psychological, and environmental factors, and no single mechanism explains every patient’s response to treatment.
Spravato may be considered for certain adults with treatment-resistant depression.
A clinician will typically consider factors such as:
A thorough evaluation is important because Spravato isn’t appropriate for everyone.
Spravato treatment follows a structured process. Before administration, the healthcare team evaluates the patient and checks blood pressure. The medication is then administered as a nasal spray under direct supervision. Patients remain at the healthcare facility for observation afterward.
The FDA prescribing information recommends monitoring for at least two hours because of risks including sedation, dissociation, and respiratory depression. Blood pressure is also reassessed after dosing.
Because of these effects, patients should follow their treatment center’s instructions regarding transportation and activities after treatment.
Spravato can cause side effects, and patients should understand them before starting treatment.
Potential adverse effects include:
The medication also carries warnings related to abuse and misuse. Because of these risks, Spravato is available through the SPRAVATO REMS, a restricted safety program. Your healthcare provider can explain the potential benefits and risks based on your individual health history.
This is an area where careful wording matters.
The FDA has approved Spravato, with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior.
However, the FDA specifically states that the effectiveness of Spravato in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. Therefore, Spravato should not be described as a proven suicide-prevention treatment.
Anyone experiencing suicidal thoughts or feeling unable to stay safe should receive immediate professional evaluation and crisis support rather than waiting for a routine Spravato appointment.
Consider speaking with a qualified mental health professional if depression continues despite treatment or is interfering with your ability to work, maintain relationships, sleep, or manage everyday responsibilities.
If Spravato is appropriate, your provider can also explain the expected treatment process, monitoring requirements, potential risks, and alternatives.
Spravato is FDA-approved for treatment-resistant depression in adults. However, individual responses vary, and a clinician should determine whether it is appropriate for a particular patient.
Spravato contains esketamine and works through the glutamate system by antagonizing NMDA receptors. This differs from many traditional antidepressants that primarily affect serotonin, norepinephrine, or related neurotransmitter systems.
For adults with treatment-resistant depression, current FDA labeling allows Spravato to be used as monotherapy or alongside an oral antidepressant.
No. Spravato must be administered under direct supervision in an appropriate healthcare setting, followed by monitoring.
The current prescribing information requires monitoring for at least two hours after administration, with assessment to determine when the patient is clinically stable.
No. Spravato is a treatment option, not a guaranteed cure. Treatment response varies, and ongoing clinical evaluation is important.
Living with depression that hasn’t improved enough with previous treatments can leave you feeling like you’ve run out of options. You haven’t necessarily run out of options but finding the right one requires a careful, individualized approach.
The benefits of Spravato for depression include providing another FDA-approved treatment pathway for adults with treatment-resistant depression, using a different mechanism from many traditional antidepressants, and offering treatment within a structured, medically supervised setting.
But Spravato isn’t right for everyone. Its potential benefits, risks, monitoring requirements, and alternatives should be discussed with a qualified mental health professional.
If you or someone you care about is struggling with depression that hasn’t improved with previous treatment, Pinnacle Behavioral Healthcare can help you explore your options. Contact Pinnacle Behavioral Healthcare to schedule an evaluation and discuss whether Spravato or another evidence-based treatment may be appropriate for your needs.
